- Design
- repeated cross-sectional analysis of a national longitudinal prescription dataset, 2013 to 2024
- Population
- 1,100,233,787 benzodiazepine prescription fills in the United States, by patient age and prescriber type
- Primary outcome
- annual dispensing prevalence, fill counts and mean total dose per prescription
- Effect
- prevalence fell 26.7% (7.5% to 5.5%); ages 18-29 fell 44.8%; advanced practice providers rose 101.5%
A repeated cross-sectional analysis of the IQVIA longitudinal prescription dataset covered 1,100,233,787 benzodiazepine fills in the United States between 2013 and 2024, reporting fill counts, population prevalence and mean total dose per prescription by patient age and prescriber type.
Annual dispensing prevalence fell 26.7%, from 7.5% of the population to 5.5%. The decline ran across every age band and was steepest in adults aged 18 to 29, down 44.8%. Mean total dose per prescription also fell in every age group and every prescriber group, most sharply for pain medicine specialists at 65.3% — so prescriptions became both fewer and smaller.
By prescriber the picture diverges. Pain medicine fell 62.5%, primary care 44.3% and psychiatry 38.3%. Advanced practice providers went the other way, rising 101.5%. Primary care still writes the largest absolute number of benzodiazepine prescriptions, ahead of advanced practice providers and psychiatrists.
This is dispensing data from one country, and it describes what happened rather than whether patients benefited. Its use in clinic is as a reference point: a psychiatric practice whose benzodiazepine prescribing has not moved over this decade is now an outlier against its peers, and the doubling among advanced practice providers identifies where deprescribing support and supervision are most likely to be needed. Indian dispensing patterns are not captured here, and clonazepam prescribing in particular has no comparable national dataset.
- Use the decade trend as a benchmark: falling fills and falling dose per prescription is the direction of travel among specialists
- Review who in your service initiates benzodiazepines, not only how many are initiated — prescriber mix is where the change was uneven
- When taking over care of a long-term benzodiazepine user, record the indication and the planned duration explicitly
- For a patient aged under 30 on a benzodiazepine, treat the prescription as one to justify rather than continue by default
- Do not read a national dispensing fall as evidence that current prescribing is appropriate — this study cannot judge that
Why it matters
A prescribing pattern that has not changed in ten years is now out of step with everyone else's, which is worth knowing before an audit says so.
Don't overread it
Dispensing trends cannot show whether prescribing improved — a fall could equally reflect undertreated anxiety.
The statistics, in plain English
These are counts and percentages from a near-complete prescription dataset, not estimates, so there are no confidence intervals to interpret and precision is not the issue. What the numbers cannot tell you is why: a 26.7% fall is consistent with more appropriate prescribing, with undertreatment of severe anxiety, or with patients moving to other sedatives, and nothing here distinguishes them. The 101.5% rise among advanced practice providers is a relative change on a smaller base and partly reflects growth in that workforce.
Read the rest in the app
You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.
Scan to keep reading on your phone. No account needed to start.
Tomorrow morning, before your first patient
One edition a day for psychiatry, written by the desk, every claim tied to its paper. Six minutes.
Get the app — free